Albion Financial Group UT Trims Stock Position in KORU Medical Systems, Inc. (NASDAQ:KRMD)

Albion Financial Group UT lessened its holdings in KORU Medical Systems, Inc. (NASDAQ:KRMD - Free Report) by 22.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 441,374 shares of the company's stock after selling 125,000 shares during the quarter. Albion Financial Group UT owned about 0.96% of KORU Medical Systems worth $1,121,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jefferies Financial Group Inc. purchased a new stake in shares of KORU Medical Systems in the fourth quarter worth $132,000. Vivaldi Capital Management LP bought a new position in KORU Medical Systems in the 4th quarter worth about $82,000. Point72 Asia Singapore Pte. Ltd. grew its position in KORU Medical Systems by 145.6% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 31,818 shares of the company's stock valued at $122,000 after purchasing an additional 18,863 shares during the last quarter. Millennium Management LLC grew its position in KORU Medical Systems by 4.5% during the 4th quarter. Millennium Management LLC now owns 283,710 shares of the company's stock valued at $1,092,000 after purchasing an additional 12,187 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in KORU Medical Systems during the 4th quarter valued at about $84,000. Hedge funds and other institutional investors own 58.60% of the company's stock.

Analysts Set New Price Targets

KRMD has been the topic of several analyst reports. B. Riley upgraded shares of KORU Medical Systems to a "strong-buy" rating in a research note on Thursday, March 13th. Piper Sandler decreased their price objective on shares of KORU Medical Systems from $4.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, May 8th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $4.50.

KORU Medical Systems Stock Performance

NASDAQ:KRMD traded down $0.02 during mid-day trading on Thursday, reaching $3.62. The company's stock had a trading volume of 106,116 shares, compared to its average volume of 142,655. The company has a current ratio of 2.44, a quick ratio of 2.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $167.03 million, a P/E ratio of -32.91 and a beta of 0.52. The firm's fifty day moving average price is $3.04 and its two-hundred day moving average price is $3.33. KORU Medical Systems, Inc. has a 12-month low of $1.86 and a 12-month high of $5.05.

KORU Medical Systems (NASDAQ:KRMD - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The company had revenue of $9.64 million during the quarter, compared to the consensus estimate of $8.86 million. KORU Medical Systems had a negative return on equity of 30.43% and a negative net margin of 15.09%. On average, equities analysts forecast that KORU Medical Systems, Inc. will post -0.13 EPS for the current fiscal year.

KORU Medical Systems Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.